サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ウイルスベクター・プラスミドDNA製造市場 - 成長、将来展望、競合分析、2023年～2031年
市場調査レポート
商品コード
1293832

ウイルスベクター・プラスミドDNA製造市場 - 成長、将来展望、競合分析、2023年～2031年

Viral Vectors and Plasmid DNA Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ウイルスベクター・プラスミドDNA製造市場 - 成長、将来展望、競合分析、2023年～2031年
出版日: 2023年06月01日
発行: Acute Market Reports
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ウイルスベクター・プラスミドDNA製造市場は、先進的な遺伝子治療、ワクチン、細胞ベースの治療に対する需要の増加により、2023年から2031年の予測期間中に22.5%のCAGRで成長すると予測されています。市場収益は、今後数年間、有望な年間平均成長率（CAGR）で大幅な成長を遂げると予想されます。ウイルスベクターとプラスミドDNAは、遺伝子治療やワクチンの開発・生産に不可欠なコンポーネントです。アデノウイルス、レンチウイルス、アデノ随伴ウイルス（AAV）などのウイルスベクターは、遺伝物質を標的細胞に導入するために使用され、さまざまな病気に関連する特定の遺伝子を変更または修正することができます。一方、プラスミドDNAは、治療用遺伝子を運ぶためのビークルとして機能し、細胞内でのタンパク質合成に必要な命令を提供します。ウイルスベクター・プラスミドDNA製造市場は、バイオテクノロジーと遺伝子工学の進歩により、医療の分野に革命的な変化をもたらしています。遺伝子治療薬は、さまざまな遺伝性疾患、希少疾患、ある種のがんの治療において大きな可能性を示しています。さらに、感染症を標的としたワクチンやがんの免疫療法の開発が、ウイルスベクター・プラスミドDNA製造の需要をさらに押し上げています。COVID-19のパンデミックは、ワクチンや治療法を開発するための研究開発活動を急増させ、この市場の成長をさらに加速させています。複数の製薬会社や研究機関が、COVID-19ワクチンや治療薬を開発するために、ウイルスベクターやプラスミドDNAを活用することに力を注いでいます。この前例のない世界の健康危機は、新興感染症や公衆衛生上の課題に対処するためのウイルスベクター・プラスミドDNA製造能力の重要性を浮き彫りにしています。

高まる遺伝子治療への需要

ウイルスベクター・プラスミドDNA製造市場は、遺伝子治療への需要の高まりによって牽引されています。遺伝子治療は、患者の細胞に機能的な遺伝子を導入することで、さまざまな遺伝性疾患や遺伝性疾病を治療する有望なアプローチとなります。筋ジストロフィー、嚢胞性線維症、血友病などの遺伝性疾患の有病率の増加が、遺伝子治療への需要を促進しています。Journal of the American Medical Association（JAMA）に掲載された研究によると、遺伝子治療は様々な遺伝性疾患に対する臨床試験で大きな治療効果を示しています。これまで治療不可能であった疾患や、治療の選択肢が限られていた疾患に対する遺伝子治療の成功は、その製造に使用されるウイルスベクターやプラスミドDNAに対する市場の強い需要を生み出しました。

ウイルスベクター技術の進歩

ウイルスベクター技術の進歩は、ウイルスベクター・プラスミドDNA製造市場の成長を促進する上で重要な役割を担っています。研究者やバイオ医薬品企業は、遺伝子治療やワクチンに使用されるウイルスベクターの効率性、安全性、特異性の向上に絶えず取り組んでいます。例えば、遺伝子導入能力を強化し、免疫原性を低減した新世代のアデノ随伴ウイルス（AAV）の開発は、いくつかの遺伝子治療試験の成功に寄与しています。また、「Molecular Therapy」誌に掲載された研究では、効率的な遺伝子導入を実現するための新しいAAVの変種の可能性が示されました。このようなウイルスベクター技術の進歩は、遺伝子治療の有効性を向上させるだけでなく、さまざまな治療分野への応用を広げ、ウイルスベクター・プラスミドDNA製造の需要をさらに押し上げています。

バイオテクノロジー研究開発への投資の増加

ウイルスベクター・プラスミドDNA製造市場は、バイオテクノロジーの研究開発への投資の増加によって推進されています。政府、製薬会社、研究機関は、遺伝子治療やワクチンなどの革新的な治療法の開発に多額の資金を割り当てています。例えば、米国の国立衛生研究所（NIH）は、遺伝子治療の研究や臨床試験の支援に多額の資金を投入しています。また、欧州連合（EU）は、バイオテクノロジーと遺伝子治療イニシアチブを推進するために、「Horizon 2020」プログラムを通じて多額の資金を投入しています。このような研究開発への投資は、新規技術の発見を促し、先進的な治療法の商業化につながります。バイオテクノロジーの研究開発に対する財政支援と集中力の高まりは、今後数年間、ウイルスベクター・プラスミドDNA製造市場を牽引すると予想されます。

規制上の課題および安全性への懸念

ウイルスベクター・プラスミドDNA製造市場は、規制上の課題と安全性の懸念に直面しており、これが市場成長の抑制要因となっています。遺伝子治療薬やワクチンの開発・商業化には、製品の有効性と安全性を確保するための厳しい規制プロセスや安全性評価が必要です。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、ウイルスベクターやプラスミドDNAの製造、品質管理、臨床試験について厳しいガイドラインや要件を課しています。これらの規制を遵守することは、メーカーにとって時間と費用がかかるため、製品の承認や市場参入の遅れにつながる可能性があります。さらに、免疫反応、オフターゲット効果、長期的な安全性プロファイルなど、遺伝子治療に関連する潜在的なリスクに関する懸念は、これらの治療法の普及に向けた課題となっています。臨床試験における有害事象や安全性に関する報告は、遺伝子治療に対する認識や受容性に影響を与え、ウイルスベクター・プラスミドDNA製造の需要に影響を与える可能性があります。例えば、X-連鎖性重症複合免疫不全症（X-SCID）治療のための遺伝子治療試験をめぐる安全性の懸念は、試験の一時停止につながっています。このような規制上の課題や安全性への懸念は、遺伝子治療やワクチンの安全性や有効性を確保するために、規制を厳格に遵守し、研究を継続する必要があり、ウイルスベクター・プラスミドDNA製造市場にとって抑制要因となります。

ベクタータイプ別ではアデノウイルスベクターが市場を席巻

ウイルスベクター・プラスミドDNA製造市場は、アデノウイルス、レトロウイルス、アデノ随伴ウイルス（AAV）、レンチウイルス、プラスミドなど、ベクターの種類によって区分することができます。これらの中で、AAVは2023年から2031年の予測期間中に最も高いCAGRを記録すると予想されています。AAVベクターは、低い免疫原性と長期的な遺伝子発現で治療用遺伝子を効率的に標的細胞に送り込むことができるため、遺伝子治療用途において大きな注目を集めています。LuxturnaやZolgensmaなど、承認された遺伝子治療薬にAAVベクターが使用されたことで、遺伝性疾患の治療におけるAAVベクターの可能性が示されました。その結果、AAVベクターの需要が増加し、CAGRの観点から市場の成長を牽引しています。ウイルスベクター・プラスミドDNA製造市場において、2022年の売上高では、アデノウイルスベクターが最も高いシェアを占めています。アデノウイルスベクターは、その高い導入効率と大きなDNA挿入を収容する能力により、遺伝子治療研究および臨床試験で広く使用されています。特に、がん免疫療法やワクチン開発など、いくつかの遺伝子治療用途で成功を収めています。さらに、アデノウイルスベクターの堅牢な製造プロセスと確立されたプロトコールは、市場におけるアデノウイルスベクターの支配的な収益ポジションに貢献しています。レンチウイルスを含むレトロウイルスベクターも、CAR-T細胞療法や遺伝子改変細胞療法での使用が主な要因となり、大きな収益シェアを占めています。遺伝子クローニングや組み換えDNA技術に不可欠なツールであるプラスミドは、市場の収益に貢献していますが、成長率は比較的低めです。単純ヘルペスウイルス（HSV）ベクターやワクシニアウイルスベクターなどの他のベクタータイプは、市場での売上シェアは小さいです。要約すると、アデノウイルスベクターが最も高い収益を上げる一方で、AAVベクターは遺伝子治療への応用が期待できることから、最も高いCAGRを記録すると予想されます。

北米が収益をリードする一方、アジア太平洋が成長をリードする

2022年のウイルスベクター・プラスミドDNA製造市場では、北米が収益面で大きなシェアを占めています。この地域は、確立されたバイオ医薬品産業、強固な研究インフラ、遺伝子治療やワクチンの開発・商業化を促進する有利な規制の枠組みを有しています。さらに、特に米国では研究開発活動への投資が増加しており、市場の収益拡大に寄与しています。また、欧州はウイルスベクター・プラスミドDNA製造市場において顕著な地域であり、収益貢献度が高いです。大手バイオ医薬品企業の存在、バイオテクノロジー研究の進展、政府の強力なサポートが、この地域の市場成長を後押ししています。2023年から2031年の予測期間中に最も高いCAGRを示すという点では、アジア太平洋がトップに立つと予想されます。この地域は、研究開発への投資の増加、医療支出の増加、個別化医療への注目の高まりなどの要因によって、バイオテクノロジー分野の急成長を示しています。中国、日本、インドなどの国々は、科学的専門知識を活用し、バイオ医薬品の能力を拡大することで、ウイルスベクター・プラスミドDNA製造市場の主要プレーヤーとして浮上しています。また、ラテンアメリカや中東・アフリカ地域も、医療インフラの改善や先進医療技術の導入に力を入れるようになり、市場の着実な成長が見られるようになってきています。

市場競争は予測期間中に激化

ウイルスベクター・プラスミドDNA製造市場は競争が激しく、複数の主要企業が遺伝子治療やワクチン用のウイルスベクターやプラスミドDNAの開発・生産に積極的に参加しています。これらの企業は、市場での存在感を高め、競争力を獲得するために戦略的な取り組みに注力しています。市場のトップ企業の1つは、世界の開発・製造受託機関（CDMO）であるLonza Groupです。Lonzaは、ウイルスベクターの製造、プラスミドDNAの製造、プロセス開発など、幅広いサービスを提供しています。市場のトップ企業などが採用する主な戦略には、製造プロセスを強化するための研究開発活動への投資、需要の増加に対応するための生産能力の拡大、新規技術へのアクセスや市場参入を広げるための戦略的パートナーシップや提携の確立などがあります。また、これらの企業は、遺伝子治療およびワクチン業界の厳しい要件を満たすために、規制遵守、品質保証、適正製造規範の遵守の確保に注力しています。さらに、ウイルスベクター・プラスミドDNA製造市場の競争は、革新的な技術やプラットフォームで市場に参入する新興企業やスタートアップ企業によってさらに激化しています。これらの企業は、バイオテクノロジーと遺伝子工学の進歩を活用して、新しいウイルスベクター・プラスミドDNA製造のアプローチを開発しています。

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

第3章 ウイルスベクター・プラスミドDNA製造市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs 2031

第4章 ウイルスベクター・プラスミドDNA製造市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のウイルスベクター・プラスミドDNA製造市場金額 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 ウイルスベクター・プラスミドDNA製造市場：ベクタータイプ別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • アデノウイルス
    • レトロウイルス
    • アデノ随伴ウイルス（AAV）
    • レンチウイルス
    • プラスミド
    • その他

第6章 ウイルスベクター・プラスミドDNA製造市場：ワークフロー別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 上流の製造工程
      • ベクター増幅・拡張
      • ベクター回収/収集
    • 下流の製造工程
      • 精製
      • 充填・仕上げ

第7章 ウイルスベクター・プラスミドDNA製造市場：用途別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • アンチセンス・RNAi療法
    • 遺伝子治療
    • 細胞治療
    • ワクチン開発
    • 研究用途

第8章 ウイルスベクター・プラスミドDNA製造市場：最終用途別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 製薬企業・バイオ医薬品企業
    • 研究機関

第9章 ウイルスベクター・プラスミドDNA製造市場：疾患別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • がん
    • 遺伝性疾患
    • 感染症
    • その他

第10章 北米のウイルスベクター・プラスミドDNA製造市場 2021-2031

  • 市場概要
  • ウイルスベクター・プラスミドDNA製造市場：ベクタータイプ別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：ワークフロー別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：最終用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：疾患別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：地域別 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第11章 英国・欧州連合のウイルスベクター・プラスミドDNA製造市場 2021-2031

  • 市場概要
  • ウイルスベクター・プラスミドDNA製造市場：ベクタータイプ別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：ワークフロー別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：最終用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：疾患別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：地域別 2021-2031
    • 英国・欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第12章 アジア太平洋のウイルスベクター・プラスミドDNA製造市場 2021-2031

  • 市場概要
  • ウイルスベクター・プラスミドDNA製造市場：ベクタータイプ別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：ワークフロー別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：最終用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：疾患別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：地域別 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第13章 ラテンアメリカのウイルスベクター・プラスミドDNA製造市場 2021-2031

  • 市場概要
  • ウイルスベクター・プラスミドDNA製造市場：ベクタータイプ別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：ワークフロー別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：最終用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：疾患別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：地域別 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第14章 中東・アフリカのウイルスベクター・プラスミドDNA製造市場 2021-2031

  • 市場概要
  • ウイルスベクター・プラスミドDNA製造市場：ベクタータイプ別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：ワークフロー別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：最終用途別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：疾患別 2021-2031
  • ウイルスベクター・プラスミドDNA製造市場：地域別 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第15章 企業プロファイル

  • Lonza
  • Catapult
  • uniQure N.V.
  • FUJIFILM Diosynth Biotechnologies
  • Kaneka Eurogentec S.A.
  • Oxford Biomedica
  • Spark Therapeutics Inc.
  • Cobrabiologics
  • Merck KGaA
  • その他の注目企業
図表

List of Tables

  • TABLE 1 Global Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 2 Global Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 3 Global Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 4 Global Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 5 Global Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 6 Global Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 7 Global Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 8 North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 9 North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 10 North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 11 North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 12 North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 13 North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 14 North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 15 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 16 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 17 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 18 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 20 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 21 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 22 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 23 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 24 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 25 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 26 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 27 Canada Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 28 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 29 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 30 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 31 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 32 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 33 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 34 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 35 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 36 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 37 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 38 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 39 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 40 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 41 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 42 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 43 UK Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 44 UK Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 45 UK Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 46 UK Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 47 UK Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 48 UK Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 49 UK Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 50 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 51 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 52 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 53 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 54 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 55 Germany Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 56 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 57 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 58 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 59 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 60 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 61 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 62 Spain Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 63 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 64 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 65 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 66 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 67 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 68 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 69 Italy Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 71 France Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 72 France Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 73 France Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 74 France Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 75 France Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 76 France Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 77 France Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 78 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 79 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 80 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 81 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 82 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 83 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 84 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 85 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 86 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 87 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 88 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 89 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 90 Asia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 91 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 92 China Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 93 China Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 94 China Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 95 China Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 96 China Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 97 China Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 98 China Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 99 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 100 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 101 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 102 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 103 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 104 Japan Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 105 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 106 India Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 107 India Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 108 India Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 109 India Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 110 India Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 111 India Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 112 India Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 113 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 114 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 115 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 116 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 117 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 118 Australia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 119 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 120 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 121 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 122 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 123 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 124 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 126 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 127 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 128 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 134 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 135 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 136 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 137 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 138 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 139 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 140 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 141 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 143 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 144 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 145 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 146 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 147 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 148 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 149 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 150 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 151 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 152 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 153 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 154 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 155 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 156 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 157 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 158 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 159 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 160 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 161 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 162 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 163 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 164 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 165 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 166 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 167 GCC Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 168 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 169 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 170 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 171 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 172 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 173 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 174 Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 175 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 176 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 177 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 178 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 179 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 180 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 181 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 182 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Viral Vectors and Plasmid DNA Manufacturing Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Viral Vectors and Plasmid DNA Manufacturing Market: Quality Assurance
  • FIG. 5 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022
  • FIG. 6 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022
  • FIG. 7 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022
  • FIG. 8 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022
  • FIG. 9 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022
  • FIG. 10 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022
  • FIG. 11 Market Geographical Opportunity Matrix - Global Viral Vectors and Plasmid DNA Manufacturing Market, 2022

FIG. 12Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Players, 2022

FIG. 13Global Viral Vectors and Plasmid DNA Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 14 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 Vs 2031, %
  • FIG. 15 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 Vs 2031, %
  • FIG. 16 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 Vs 2031, %
  • FIG. 17 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 Vs 2031, %
  • FIG. 18 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 Vs 2031, %
  • FIG. 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 20 Canada Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 22 UK Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 23 Germany Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 24 Spain Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 25 Italy Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 26 France Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 28 China Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 29 Japan Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 30 India Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 31 Australia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 32 South Korea Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Asia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 34 Brazil Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 35 Mexico Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 36 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 37 GCC Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 38 Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 39 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
目次
Product Code: 139601-06-23

The viral vectors and plasmid DNA manufacturing market is expected to grow at a CAGR of 22.5% during the forecast period of 2023 to 2031, driven by the increasing demand for advanced gene therapies, vaccines, and cell-based therapies. The market revenue is expected to witness substantial growth in the coming years, with a promising compound annual growth rate (CAGR).Viral vectors and plasmid DNA are essential components in the development and production of gene therapies and vaccines. Viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are used to deliver genetic material into target cells, enabling the modification or correction of specific genes associated with various diseases. Plasmid DNA, on the other hand, serves as a vehicle for carrying therapeutic genes, providing the necessary instructions for protein synthesis within cells.The market for viral vectors and plasmid DNA manufacturing is driven by advancements in biotechnology and genetic engineering, which have revolutionized the field of medicine. Gene therapies have shown tremendous potential in treating a range of genetic disorders, rare diseases, and certain types of cancer. Additionally, the development of vaccines targeting infectious diseases and immunotherapies for cancer has further propelled the demand for viral vectors and plasmid DNA manufacturing.The COVID-19 pandemic has further accelerated the growth of this market, with a surge in research and development activities to develop vaccines and treatments. Several pharmaceutical companies and research organizations have focused their efforts on leveraging viral vectors and plasmid DNA to develop COVID-19 vaccines and therapeutics. This unprecedented global health crisis has highlighted the importance of viral vectors and plasmid DNA manufacturing capabilities in addressing emerging infectious diseases and public health challenges.

Growing Demand for Gene Therapies

The viral vectors and plasmid DNA manufacturing market is driven by the growing demand for gene therapies. Gene therapy offers a promising approach to treat a wide range of genetic disorders and inherited diseases by introducing functional genes into patients' cells. The increasing prevalence of genetic diseases, such as muscular dystrophy, cystic fibrosis, and hemophilia, has fuelled the demand for gene therapies. According to a study published in the Journal of the American Medical Association (JAMA), gene therapy has shown significant therapeutic benefits in clinical trials for various genetic disorders. The success of gene therapies in treating diseases that were previously untreatable or had limited treatment options has generated a strong market demand for viral vectors and plasmid DNA used in their manufacturing.

Advancements in Viral Vector Technology

Advancements in viral vector technology play a crucial role in driving the growth of the viral vectors and plasmid DNA manufacturing market. Researchers and biopharmaceutical companies are constantly working on improving the efficiency, safety, and specificity of viral vectors used in gene therapies and vaccines. For example, the development of new generation adeno-associated viruses (AAVs) with enhanced transduction capabilities and reduced immunogenicity has contributed to the success of several gene therapy trials. A study published in the journal Molecular Therapy demonstrated the potential of novel AAV variants in achieving efficient gene delivery. These advancements in viral vector technology have not only improved the efficacy of gene therapies but also expanded their application in various therapeutic areas, further driving the demand for viral vectors and plasmid DNA manufacturing.

Increasing Investments in Biotechnology Research and Development

The viral vectors and plasmid DNA manufacturing market is propelled by increasing investments in biotechnology research and development. Governments, pharmaceutical companies, and research institutions are allocating significant funds for the development of innovative therapies, including gene therapies and vaccines. For instance, the National Institutes of Health (NIH) in the United States has invested substantial resources in supporting gene therapy research and clinical trials. The European Union has also committed significant funding through its Horizon 2020 program for advancing biotechnology and gene therapy initiatives. These investments in research and development activities fuel the discovery of novel viral vectors and plasmid DNA manufacturing technologies, leading to the commercialization of advanced therapies. The growing financial support and focus on biotechnology research and development are expected to drive the viral vectors and plasmid DNA manufacturing market in the coming years.

Regulatory Challenges and Safety Concerns

The viral vectors and plasmid DNA manufacturing market faces regulatory challenges and safety concerns that serve as a restraint to its growth. The development and commercialization of gene therapies and vaccines involve stringent regulatory processes and safety assessments to ensure the efficacy and safety of these products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose strict guidelines and requirements for the manufacturing, quality control, and clinical testing of viral vectors and plasmid DNA. Compliance with these regulations can be time-consuming and expensive for manufacturers, leading to delays in product approvals and market entry. Additionally, concerns about the potential risks associated with gene therapies, such as immune responses, off-target effects, and long-term safety profiles, pose challenges to the widespread adoption of these therapies. Reports of adverse events and safety issues in clinical trials can impact the perception and acceptance of gene therapies, affecting the demand for viral vectors and plasmid DNA manufacturing. For example, the safety concerns surrounding a gene therapy trial for the treatment of X-linked severe combined immunodeficiency (X-SCID) led to a temporary halt in the trial. These regulatory challenges and safety concerns pose a restraint to the viral vectors and plasmid DNA manufacturing market, necessitating rigorous compliance with regulations and continued research to ensure the safety and efficacy of gene therapies and vaccines.

Adenovirus Vectors Dominates the Market by Vector Type

The viral vectors and plasmid DNA manufacturing market can be segmented based on vector types, including adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Among these, AAV is expected to witness the highest CAGR during the forecast period of 2023 to 2031. AAV vectors have gained significant attention in gene therapy applications due to their ability to efficiently deliver therapeutic genes to target cells with low immunogenicity and long-term gene expression. The use of AAV vectors in approved gene therapies, such as Luxturna and Zolgensma, has showcased their potential in treating inherited genetic disorders. As a result, the demand for AAV vectors is increasing, driving the growth of the market in terms of CAGR. In terms of revenue, adenovirus vectors held the highest share in 2022 in the viral vectors and plasmid DNA manufacturing market. Adenovirus vectors are widely used in gene therapy research and clinical trials due to their high transduction efficiency and ability to accommodate large DNA inserts. They have demonstrated success in several gene therapy applications, particularly in cancer immunotherapies and vaccine development. Moreover, the robust manufacturing processes and well-established protocols for adenovirus vectors contribute to their dominant revenue position in the market. Retrovirus vectors, including lentivirus, also hold a significant revenue share, primarily driven by their use in CAR-T cell therapies and gene-modified cell therapies. Plasmids, which serve as essential tools in gene cloning and recombinant DNA technology, contribute to the market's revenue but have a comparatively lower growth rate. Other vector types, such as herpes simplex virus (HSV) vectors and vaccinia virus vectors, hold a smaller revenue share in the market. In summary, while adenovirus vectors generate the highest revenue, AAV vectors are expected to witness the highest CAGR, driven by their promising applications in gene therapies.

North America Leads the Revenues While APAC Leads the Growth

North America held a significant share in terms of revenue in the viral vectors and plasmid DNA manufacturing market in 2022. The region has a well-established biopharmaceutical industry, robust research infrastructure, and favorable regulatory frameworks that facilitate the development and commercialization of gene therapies and vaccines. Moreover, increasing investments in research and development activities, particularly in the United States, contribute to the market's revenue growth. Europe is also a prominent region in the viral vectors and plasmid DNA manufacturing market, with a significant revenue contribution. The presence of leading biopharmaceutical companies, advancements in biotechnology research, and strong government support drive the market's growth in this region. In terms of the highest CAGR during the forecast period of 2023 to 2031, Asia Pacific is expected to top the ranl. The region has witnessed rapid growth in the biotechnology sector, driven by factors such as increasing investments in research and development, rising healthcare expenditure, and a growing focus on personalized medicine. Countries like China, Japan, and India are emerging as key players in the viral vectors and plasmid DNA manufacturing market, leveraging their scientific expertise and expanding biopharmaceutical capabilities. Latin America and the Middle East and Africa regions are also witnessing steady growth in the market, driven by the increasing focus on improving healthcare infrastructure and the adoption of advanced medical technologies.

Market Competition to Intensify During the Forecast Period

The viral vectors and plasmid DNA manufacturing market is highly competitive, with several key players actively participating in the development and production of viral vectors and plasmid DNA for gene therapies and vaccines. These companies are focusing on strategic initiatives to strengthen their market presence and gain a competitive edge.One of the top players in the market is Lonza Group, a global contract development and manufacturing organization (CDMO). Lonza offers a wide range of services, including viral vector manufacturing, plasmid DNA production, and process development.Key strategies adopted by top players and others in the market include investing in research and development activities to enhance manufacturing processes, expanding production capacity to meet the growing demand, and establishing strategic partnerships and collaborations to access novel technologies and broaden their market reach. These companies are also focusing on ensuring regulatory compliance, quality assurance, and adherence to good manufacturing practices to meet the stringent requirements of the gene therapy and vaccine industry. Moreover, competition in the viral vectors and plasmid DNA manufacturing market is further intensified by emerging players and start-ups that are entering the market with innovative technologies and platforms. These players are leveraging advancements in biotechnology and genetic engineering to develop novel viral vectors and plasmid DNA manufacturing approaches.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofViral Vectors and Plasmid DNA Manufacturing market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Viral Vectors and Plasmid DNA Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

Workflow

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

Application

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

End-use

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Viral Vectors and Plasmid DNA Manufacturing market?
  • Which is the largest regional market for Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Viral Vectors and Plasmid DNA Manufacturing market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Vectors and Plasmid DNA Manufacturing market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Viral Vectors and Plasmid DNA Manufacturing Market
  • 2.2. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 (US$ Million)
  • 2.3. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 (US$ Million)
  • 2.4. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 (US$ Million)
  • 2.5. Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 (US$ Million)
  • 2.6. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 (US$ Million)
  • 2.7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2022

3. Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Analysis

  • 3.1. Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Vendors
  • 3.2. Strategies Adopted by Viral Vectors and Plasmid DNA Manufacturing Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Viral Vectors and Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Viral Vectors and Plasmid DNA Manufacturing Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Adenovirus
    • 5.3.2. Retrovirus
    • 5.3.3. Adeno-Associated Virus (AAV)
    • 5.3.4. Lentivirus
    • 5.3.5. Plasmids
    • 5.3.6. Others

6. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Upstream Manufacturing
      • 6.3.1.1. Vector Amplification & Expansion
      • 6.3.1.2. Vector Recovery/Harvesting
    • 6.3.2. Downstream Manufacturing
      • 6.3.2.1. Purification
      • 6.3.2.2. Fill Finish

7. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Antisense & RNAi Therapy
    • 7.3.2. Gene Therapy
    • 7.3.3. Cell Therapy
    • 7.3.4. Vaccinology
    • 7.3.5. Research Applications

8. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Pharmaceutical and Biopharmaceutical Companies
    • 8.3.2. Research Institutes

9. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 9.3. Market Segmentation
    • 9.3.1. Cancer
    • 9.3.2. Genetic Disorders
    • 9.3.3. Infectious Diseases
    • 9.3.4. Others

10. North America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 10.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 10.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 10.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 10.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 10.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

11. UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 11.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 11.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 11.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 11.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 11.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

12. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 12.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 12.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 12.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 12.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 12.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 13.1. Market Overview
  • 13.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 13.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 13.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 13.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 13.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 13.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

14. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 14.1. Market Overview
  • 14.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 14.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 14.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 14.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 14.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 14.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

15. Company Profile

  • 15.1. Lonza
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. Catapult
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. uniQure N.V.
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. FUJIFILM Diosynth Biotechnologies
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. Kaneka Eurogentec S.A.
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. Oxford Biomedica
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. Spark Therapeutics, Inc.
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. Cobrabiologics
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. Merck KGaA
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. Other Notable Players
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives